High number of hypoglycaemic episodes identified by CGM among home-dwelling older people with diabetes: an observational study in Norway.

"Declarations Ethics approval and consent to participateThe study protocol was approved by the Regional Committee for Medical and Health Research Ethics (REK South-East) (2018/512). This research project was conducted in accordance with the Helsinki Declaration. Each participant was completely informed about the study protocol and provided a written and informed consent form before taking part in the study. Consent for publicationNot applicable. Competing interestsAnne Haugstvedt has received lecture fees from Novo Nordisk. Trond Geir Jenssen has received lecture fees from Novo Nordisk, Eli Lilly, Astra Zeneca and Boehringen Ingelheim. Eirik Søfteland has received lecture fees from Novo Nordisk, Boehringen Ingelheim, Astra Zeneca, Otsuko Pharma, Eli Lilly and Sanofi Aventis.Other authors declared no competing interests. Competing interests Anne Haugstvedt has received lecture fees from Novo Nordisk. Trond Geir Jenssen has received lecture fees from Novo Nordisk, Eli Lilly, Astra Zeneca and Boehringen Ingelheim. Eirik Søfteland has received lecture fees from Novo Nordisk, Boehringen Ingelheim, Astra Zeneca, Otsuko Pharma, Eli Lilly and Sanofi Aventis. Other authors declared no competing interests."

"Funding The Norwegian Diabetes Association, the Olga og Minius Øieren Stiftelse, and the Western Norway University of Applied Sciences funded the study."